Detalhe da pesquisa
1.
Upadacitinib Induction and Maintenance Therapy for Crohn's Disease.
N Engl J Med
; 388(21): 1966-1980, 2023 May 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-37224198
2.
Ulcerative colitis.
Lancet
; 402(10401): 571-584, 2023 08 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37573077
3.
Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies.
Lancet
; 401(10383): 1159-1171, 2023 04 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36871574
4.
Risk of Cancer Recurrence in Patients With Immune-Mediated Diseases With Use of Immunosuppressive Therapies: An Updated Systematic Review and Meta-Analysis.
Clin Gastroenterol Hepatol
; 22(3): 499-512.e6, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37579866
5.
Washout Periods in Inflammatory Bowel Disease Trials: A Systematic Literature Review and Proposed Solutions.
Clin Gastroenterol Hepatol
; 22(4): 896-898.e13, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-37743039
6.
Comparative Efficacy of Advanced Therapies for Achieving Endoscopic Outcomes in Crohn's Disease: A Systematic Review and Network Meta-Analysis.
Clin Gastroenterol Hepatol
; 2024 Jan 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38185396
7.
Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study.
Gastroenterology
; 165(6): 1443-1457, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37659673
8.
Upadacitinib Achieves Clinical and Endoscopic Outcomes in Crohn's Disease Regardless of Prior Biologic Exposure.
Clin Gastroenterol Hepatol
; 2024 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38492904
9.
Long-term outcome of risankizumab in Crohn's disease: a real-world GETAID study.
Clin Gastroenterol Hepatol
; 2024 May 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38729389
10.
Efficacy and Safety of Ustekinumab for Ulcerative Colitis Through 4 Years: Final Results of the UNIFI Long-Term Maintenance Study.
Am J Gastroenterol
; 2024 Jan 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-38095692
11.
Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn's disease and ulcerative colitis included in randomised controlled trials.
BMC Gastroenterol
; 24(1): 121, 2024 Mar 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-38539103
12.
Harnessing the Vnn1 pantetheinase pathway boosts short chain fatty acids production and mucosal protection in colitis.
Gut
; 72(6): 1115-1128, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36175116
13.
Gut virome-colonising Orthohepadnavirus genus is associated with ulcerative colitis pathogenesis and induces intestinal inflammation in vivo.
Gut
; 72(10): 1838-1847, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36788014
14.
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial.
Lancet
; 399(10340): 2031-2046, 2022 05 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-35644155
15.
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials.
Lancet
; 399(10340): 2015-2030, 2022 05 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-35644154
16.
Evolving Short- and Long-Term Goals of Management of Inflammatory Bowel Diseases: Getting It Right, Making It Last.
Gastroenterology
; 162(5): 1424-1438, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34995529
17.
Identifying, Understanding, and Managing Fecal Urgency in Inflammatory Bowel Diseases.
Clin Gastroenterol Hepatol
; 21(6): 1403-1413.e27, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36906079
18.
Noninvasive Assessment of Postoperative Disease Recurrence in Crohn's Disease: A Multicenter, Prospective Cohort Study on Behalf of the Italian Group for Inflammatory Bowel Disease.
Clin Gastroenterol Hepatol
; 21(12): 3143-3151, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36521739
19.
Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled Trials.
Gastroenterology
; 162(2): 482-494, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34757139
20.
Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Crohn's Disease.
Gastroenterology
; 162(2): 495-508, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34748774